Index
RUT
Market Cap
79.88M
Enterprise Value
-31.55M
Income
-116.31M
Sales
0.00M
Book/sh
4.11
Cash/sh
5.96
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
36
IPO
Oct 27, 2014
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
1.00
P/C
0.69
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
3.40
Current Ratio
3.40
Debt/Eq
0.05
LT Debt/Eq
0.04
Option/Short
Yes / Yes
EPS (ttm)
-6.09
EPS next Y
-5.16
EPS next Q
-1.40
EPS this Y
-0.14%
EPS next Y
12.70%
EPS next 5Y
2.18%
EPS past 3/5Y
16.56% 32.70%
Sales past 3/5Y
- -
EPS Y/Y TTM
-10.49%
Sales Y/Y TTM
-
EPS Q/Q
4.47%
Sales Q/Q
-
Insider Own
10.22%
Insider Trans
-18.52%
Inst Own
61.79%
Inst Trans
-2.72%
ROA
-100.09%
ROE
-131.50%
ROIC
-132.27%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
3.39%
SMA50
-31.09%
SMA200
-50.91%
Trades
Shs Outstand
20.61M
Shs Float
17.36M
52W High
12.88 -67.94%
52W Low
2.81 46.98%
Volatility
18.73% 10.50%
ATR (14)
0.45
RSI (14)
43.53
Beta
2.80
Rel Volume
0.48
Avg Volume
1.06M
Volume
174,368
Perf Week
15.69%
Perf Month
-13.60%
Perf Quarter
-59.03%
Perf Half Y
-66.01%
Perf YTD
-49.26%
Perf Year
-60.36%
Perf 3Y
27.08%
Perf 5Y
-86.89%
Perf 10Y
-97.65%
Prev Close
3.93
Price
4.13
Change %
5.09%
Analysts 13 incl. previous ratings
Rating Distribution 11 Buy · 2 Hold · 0 Sell
Date Action Analyst Rating Change Price Target Change Implied Upside Apr 29, 2026 Initiated G
Buy $45 +989.6% Jul 30, 2025 Resumed R B. Riley Securities
Buy $28 +578.0% Feb 28, 2025 Initiated W
Outperform Dec 02, 2024 Initiated P
Overweight Jul 30, 2024 Initiated W
Outperform $85 +1,958.1% Jul 22, 2024 Resumed H
Buy $80 +1,837.0% Jun 26, 2024 Initiated R B. Riley Securities
Buy $85 +1,958.1% Jun 03, 2024 Reiterated O Oppenheimer
Outperform $60 → $80 +1,837.0% May 13, 2024 Initiated R RBC Capital Mkts
Outperform $77 +1,764.4% Mar 06, 2024 Upgrade J Jefferies
Hold → Buy $4 → $46 +1,013.8% Sep 08, 2020 Downgrade R
Buy → Neutral $40 → $3 -27.4% Sep 08, 2020 Downgrade R RBC Capital Mkts
Outperform → Sector Perform Sep 08, 2020 Downgrade J Jefferies
Buy → Hold $18 → $2.50 -39.5% Sep 08, 2020 Downgrade B
Buy → Neutral Jul 07, 2020 Initiated R
Buy $40 +868.5% Jun 17, 2020 Initiated B
Buy $22 +432.7% Mar 26, 2020 Initiated N
Buy $12 +190.6% Apr 05, 2019 Initiated J Jefferies
Buy Mar 20, 2019 Initiated O Oppenheimer
Outperform $28 +578.0% Jan 11, 2019 Reiterated C
Overweight $36 → $38 +820.1%
Nov-10-26 08:16AM
(Associated Press)
+11.65%
08:00AM
Nov-05-26 08:00AM
Oct-22-26 08:00AM
Sep-29-26 08:00AM
09:28AM
Loading…
Sep-14-26 09:28AM
07:00AM
Sep-11-26 04:01PM
Aug-17-26 10:00AM
Aug-06-26 08:12AM
08:00AM
Aug-04-26 08:30AM
Jul-28-26 08:00AM
Jul-06-26 08:00AM
May-26-26 07:00AM
08:00AM
Loading…
May-21-26 08:00AM
May-14-26 08:00AM
May-13-26 07:00AM
May-12-26 08:06AM
08:00AM
May-05-26 08:00AM
Apr-29-26 09:42AM
Apr-22-26 08:00AM
Apr-14-26 08:00AM
Apr-07-26 08:00AM
Mar-18-26 08:00AM
Mar-09-26 07:48AM
(Associated Press Finance)
+19.23%
07:30AM
Feb-26-26 03:08AM
Feb-12-26 08:00AM
07:30AM
Loading…
Jan-05-26 07:30AM
Dec-11-25 11:16AM
(Schaeffer's Research)
-5.65%
07:00AM
Dec-10-25 04:01PM
Nov-12-25 08:09AM
(Associated Press Finance)
+7.39%
08:00AM
Nov-06-25 08:00AM
Oct-31-25 02:40AM
Oct-30-25 04:31PM
Oct-18-25 03:00AM
Oct-14-25 08:00AM
Oct-07-25 08:00AM
Sep-22-25 08:00AM
Sep-16-25 08:00AM
Aug-08-25 10:15AM
Aug-05-25 08:11AM
(Associated Press Finance)
08:00AM
Jul-30-25 08:00AM
Jun-30-25 08:00AM
Jun-25-25 08:00AM
Jun-24-25 04:05PM
May-23-25 11:13AM
May-22-25 08:00AM
May-19-25 08:00AM
May-16-25 07:48AM
May-08-25 08:00AM
07:20AM
May-06-25 08:08AM
(Associated Press Finance)
-15.77%
08:00AM
Apr-29-25 08:14AM
Apr-18-25 09:55AM
Mar-28-25 08:00AM
Mar-20-25 09:35AM
Mar-19-25 09:35AM
Mar-13-25 12:00PM
Mar-11-25 08:17AM
(Associated Press Finance)
08:00AM
Feb-25-25 08:00AM
Feb-14-25 01:17PM
07:30AM
Feb-11-25 07:30AM
Jan-28-25 08:00AM
Jan-08-25 08:00AM
Jan-06-25 08:00AM
Dec-09-24 07:00AM
Dec-04-24 12:31PM
Dec-03-24 07:00AM
Nov-26-24 06:54AM
Nov-21-24 08:00AM
Nov-12-24 08:00AM
Nov-07-24 07:28AM
(Associated Press Finance)
07:00AM
Nov-04-24 04:10PM
(Investor's Business Daily)
+8.22%
07:00AM
Oct-29-24 08:00AM
Oct-16-24 08:00AM
Oct-15-24 07:02PM
Oct-11-24 07:02PM
Oct-03-24 05:07AM
Sep-26-24 08:00AM
Sep-24-24 09:41PM
Sep-20-24 03:18PM
Sep-12-24 07:59AM
Sep-05-24 08:00AM
Sep-04-24 07:29PM
Sep-02-24 05:22PM
Aug-27-24 08:03PM
Aug-26-24 09:55AM
Aug-21-24 05:00AM
Aug-20-24 08:00AM
Show Previous News
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Cormorant Asset Management, LP Former 10% Owner Oct 29 '26 Sale 4.10 425,000 1,742,755 1,919,971 Nov 02 04:05 PM Ben Yong Director Sep 14 '26 Sale 7.84 2,000 15,683 9,383 Sep 15 04:59 PM Saxena Nishant C Chief Business Officer Aug 11 '26 Buy 9.63 2,600 25,036 77,900 Aug 12 04:30 PM Cohen Yuval Chief Executive Officer Aug 07 '26 Sale 10.08 17,000 171,396 157,316 Aug 10 04:30 PM Moran Sean F. Chief Financial Officer Aug 07 '26 Sale 10.08 12,000 120,971 84,694 Aug 10 04:30 PM Stifel, Nicolaus & Company, In Officer Aug 07 '26 Proposed Sale 10.08 12,000 120,971 Aug 07 04:23 PM Stifel, Nicolaus & Company, In Officer Aug 07 '26 Proposed Sale 10.08 17,000 171,396 Aug 07 04:04 PM Smethurst Dominic Officer Jul 27 '26 Proposed Sale 9.20 23,025 211,818 Jul 27 04:06 PM Kung Winston Director Jun 10 '26 Sale 7.91 2,026 16,033 12,140 Jun 11 04:30 PM Altmeyer Anne Director Jun 10 '26 Sale 7.91 2,412 19,088 7,579 Jun 11 04:30 PM Jenkins John Kenneth Director Jun 10 '26 Sale 7.91 4,800 37,986 3,833 Jun 11 04:30 PM Saxena Nishant C Chief Business Officer Jun 03 '26 Buy 7.58 9,000 68,220 75,300 Jun 03 05:36 PM Saxena Nishant C Chief Business Officer Jun 02 '26 Buy 7.33 4,500 32,998 66,300 Jun 03 05:36 PM Smethurst Dominic Chief Medical Officer Mar 02 '26 Sale 8.30 6,097 50,601 89,790 Mar 04 04:30 PM Smethurst Dominic Officer Mar 02 '26 Proposed Sale 8.30 6,097 50,601 Mar 02 04:08 PM Hodgson Ian Chief Operating Officer Feb 17 '26 Sale 7.38 847 6,253 51,080 Feb 18 04:32 PM Moran Sean F. Chief Financial Officer Feb 13 '26 Sale 7.78 4,701 36,588 96,694 Feb 18 04:31 PM Cohen Yuval Chief Executive Officer Feb 13 '26 Sale 7.78 13,871 107,952 174,316 Feb 18 04:30 PM Cohen Yuval Officer Feb 13 '26 Proposed Sale 40.63 20,000 812,600 Feb 13 04:02 PM Smethurst Dominic Chief Medical Officer Feb 03 '26 Sale 8.09 3,285 26,575 95,887 Feb 04 04:25 PM Hodgson Ian Chief Operating Officer Feb 03 '26 Sale 8.09 2,415 19,537 51,927 Feb 04 04:24 PM Cormorant Asset Management, LP 10% Owner Dec 11 '25 Sale 11.46 30,029 344,012 2,344,971 Dec 15 04:18 PM
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.
CEO & Director Dr. Yuval Cohen Ph.D.
M.B.A. Mr. Sean F. Moran CPA
Ph.D. Dr. Ian Hodgson B.Sc.
M.S. Mr. G. Scott Goeken J.D.
Vice President of Human Resources Ms. Christina Bertsch M.A.
